Methods of Treating Fuchs Endothelial Corneal Dystrophy After Descemetorhexis
Summary
USPTO granted patent US12599609B2 to Kowa Company, Ltd. for methods of treating Fuchs endothelial corneal dystrophy (FECD) following descemetorhexis. The patent covers medications promoting healing in FECD patients and contains 26 claims. The inventors are Gary Gordon and Kazuhito Suehira.
What changed
USPTO issued patent US12599609B2 to Kowa Company, Ltd. for methods of treating Fuchs endothelial corneal dystrophy and medications promoting healing in FECD patients following descemetorhexis. The patent is a granted instrument conferring exclusive intellectual property rights.
For pharmaceutical companies and healthcare providers in ophthalmic therapeutics, this patent establishes proprietary rights to specific treatment protocols for FECD. Competitors developing similar treatments will need to either license the technology or design around the patented claims to avoid infringement.
What to do next
- Monitor for patent commercialization and licensing opportunities
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treating fuchs endothelial corneal dystrophy after descemetorhexis
Grant US12599609B2 Kind: B2 Apr 14, 2026
Assignee
Kowa Company, Ltd.
Inventors
Gary Gordon, Kazuhito Suehira
Abstract
Methods for treating Fuchs endothelial corneal dystrophy (“FECD”), and medications that promote healing in FECD patients following descemetorhexis.
CPC Classifications
A61K 31/551 A61P 27/02
Filing Date
2022-01-20
Application No.
18270728
Claims
26
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.